Raymond James & Associates Insmed Inc Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Insmed Inc stock. As of the latest transaction made, Raymond James & Associates holds 76,232 shares of INSM stock, worth $5.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

76,232

Previous 64,944 17.38%

Holding current value

$5.55 Million

Previous $4.35 Million 27.88%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	BUY	$62.0 - $79.01 $699,856 - $891,864	11,288 Added 17.38%	76,232 $5.56 Million
Q2 2024 Jul 19, 2024	BUY	$22.0 - $69.71 $64,746 - $205,156	2,943 Added 4.75%	64,944 $4.35 Million
Q1 2024 Apr 22, 2024	BUY	$25.72 - $29.94 $537,162 - $625,296	20,885 Added 50.8%	62,001 $1.68 Million
Q4 2023 Jan 16, 2024	SELL	$23.42 - $31.74 $72,555 - $98,330	-3,098 Reduced 7.01%	41,116 $1.27 Million
Q3 2023 Oct 24, 2023	BUY	$19.86 - $26.93 $249,699 - $338,590	12,573 Added 39.74%	44,214 $1.12 Million
Q2 2023 Jul 25, 2023	SELL	$16.44 - $21.1 $11,376 - $14,601	-692 Reduced 2.14%	31,641 $667,000
Q1 2023 Apr 14, 2023	BUY	$16.26 - $21.73 $73,852 - $98,697	4,542 Added 16.34%	32,333 $551,000
Q4 2022 Feb 08, 2023	BUY	$16.98 - $23.15 $104,104 - $141,932	6,131 Added 28.31%	27,791 $555,000
Q3 2022 Oct 25, 2022	BUY	$20.88 - $28.21 $17,748 - $23,978	850 Added 4.08%	21,660 $467,000
Q2 2022 Aug 12, 2022	SELL	$17.07 - $25.71 $1,314 - $1,979	-77 Reduced 0.37%	20,810 $410,000
Q1 2022 May 11, 2022	SELL	$20.42 - $28.13 $5,799 - $7,988	-284 Reduced 1.34%	20,887 $491,000
Q4 2021 Feb 08, 2022	SELL	$25.89 - $33.45 $20,478 - $26,458	-791 Reduced 3.6%	21,171 $577,000
Q3 2021 Nov 02, 2021	SELL	$22.46 - $29.47 $24,077 - $31,591	-1,072 Reduced 4.65%	21,962 $605,000
Q2 2021 Aug 11, 2021	BUY	$24.17 - $36.01 $17,934 - $26,719	742 Added 3.33%	23,034 $656,000
Q1 2021 May 14, 2021	SELL	$32.28 - $44.3 $18,593 - $25,516	-576 Reduced 2.52%	22,292 $759,000
Q4 2020 Feb 12, 2021	SELL	$31.45 - $40.54 $20,473 - $26,391	-651 Reduced 2.77%	22,868 $761,000
Q3 2020 Nov 04, 2020	BUY	$26.0 - $34.5 $13,494 - $17,905	519 Added 2.26%	23,519 $756,000
Q2 2020 Jul 28, 2020	BUY	$14.11 - $29.42 $82,811 - $172,665	5,869 Added 34.26%	23,000 $633,000
Q1 2020 Apr 21, 2020	SELL	$13.63 - $33.98 $2.43 Million - $6.07 Million	-178,518 Reduced 91.24%	17,131 $275,000
Q4 2019 Feb 12, 2020	BUY	$16.12 - $24.98 $296,914 - $460,106	18,419 Added 10.39%	195,649 $4.67 Million
Q3 2019 Nov 07, 2019	BUY	$15.49 - $25.78 $541,112 - $900,572	34,933 Added 24.55%	177,230 $3.13 Million
Q2 2019 Aug 06, 2019	BUY	$23.0 - $32.19 $919,448 - $1.29 Million	39,976 Added 39.07%	142,297 $3.64 Million
Q1 2019 May 06, 2019	BUY	$13.91 - $31.15 $619,885 - $1.39 Million	44,564 Added 77.16%	102,321 $2.97 Million
Q4 2018 Feb 11, 2019	BUY	$11.6 - $18.7 $338,140 - $545,105	29,150 Added 101.9%	57,757 $758,000
Q3 2018 Nov 14, 2018	BUY	$18.95 - $28.08 $542,102 - $803,284	28,607 New	28,607 $578,000

Others Institutions Holding INSM

# of Institutions

455

Shares Held

173M

Call Options Held

5.75M

Put Options Held

5.11M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $9.87B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Insmed Inc Transaction History